Can Hypnosis Therapy Treat Chronic Pain?  

By Pat Anson

The same academic institution that helped launch a nationwide crackdown on opioid medication has a new suggestion on how to treat chronic pain: hypnosis.

Researchers at the University of Washington enrolled 127 people with moderate to severe pain from spinal cord injuries in a study to see if hypnotic cognitive therapy could reduce their pain levels. 

For one hour every week for six weeks, half the participants met with a psychologist over the telephone or online Zoom calls for instructions on how to practice self-hypnosis. The other half did not get hypnosis and served as a control group. 

Both groups continued to get “usual care” for their pain throughout the study. About 75% of them were taking opioids or another prescription pain medication. 

Patients who received hypnosis were not put into a trance, like you might see on TV or in comedy acts, but received a form of cognitive behavioral therapy. Through hypnotic suggestions, patients were told to relax, breathe deeply, and imagine themselves in a comfortable place without pain. Participants were given recordings of each therapy session, and told to listen to them daily and practice self-hypnosis three times a day.

After six weeks of hypnotic therapy, participants reported that their pain levels dropped by 19.3%. Self-reported pain continued to decrease after the sessions stopped, falling by 24.5% after 12 weeks. Nearly half (46%) said their pain improved meaningfully. There were also significant improvements in sleep and depression, compared to patients in the control group.

The study was completed four years ago, but the findings are only now being published in the journal Neurology. 

“Not only did the study show that this treatment is effective, but unlike most medications used for pain, it is a treatment with many positive side effects, like improved sleep and a greater sense of self-control,” senior author Mark Jensen, PhD, a Professor of Rehabilitation Psychology at UW, said in a press release.

 “I think that, based on the evidence, including the side-effect profile, this is the first treatment that people with chronic pain should be offered.” 

Although Jensen said hypnosis should be the “first treatment” for pain, the published study indicates otherwise. The research team called hypnosis an “adjunctive treatment” for pain – which means it should be used as a secondary treatment, alongside a primary treatment such as pain medication.

Like cognitive therapy, hypnosis helps patients stop thinking that their pain won’t go away and will only become worse.  

“Hypnosis helps patients be more open to ideas about changing their thinking and internalizing those ideas,” said first author Charles Bombardier, PhD, a psychologist and Professor of Rehabilitation Medicine at UW. 

Although there’s a certain amount of stigma about hypnosis, co-author Elena Mendoza, PhD, told The Seattle Times that hypnosis is an effective way to reduce pain and is less risky than opioids.

“Hypnosis is not about what you see on the movies. It is a clinical, therapeutic technique. We use it every day in a clinical context, and it’s working well,” said Mendoza, a Research Assistant Professor at UW who specializes in hypnosis and conducted the study’s therapy sessions. 

“We really want to give people ways to manage their pain that are nonopioids. We hope this research is a step toward that,” she said.

Professors at the University of Washington have a long history of campaigning against the use of opioids. In 2007, several helped develop Washington state’s medical guideline on the use of opioids, one of the first in the country to set dosage limits.   

Professors Jane Ballantyne, MD, Gary Franklin, MD, Mark Sullivan, MD, and David Tauben, MD, were among the original members of Physicians for Responsible Opioid Prescribing (PROP), an anti-opioid activist group.

Ballantyne, Franklin and Tauben also helped draft the CDC’s controversial 2016 opioid guideline. Opioid prescribing nationwide has fallen in half since the guideline’s release.

Stem Cells Can Restore Movement in Paralyzed Patients

By Pat Anson, PNN Editor

Stem cells derived from body fat can improve sensation and restore movement in patients paralyzed by a severe spinal cord injury, according to a small clinical trial at the Mayo Clinic. One man who was paralyzed from the neck down after a surfing accident is now able to walk again after getting stem cell therapy.

"This study documents the safety and potential benefit of stem cells and regenerative medicine," first author Mohamad Bydon, MD, a Mayo Clinic neurosurgeon, said in a press release. "In spinal cord injury, even a mild improvement can make a significant difference in that patient's quality of life."

The ten patients who participated in the Phase 1 study had adipose (fat) stem calls removed from their abdomen or thigh. After several weeks, 100 million new mesenchymal stem cells (MSCs) grown in a laboratory petri dish were injected into each patient’s lumbar spine. It’s believed the cells then migrate to the injured part of the spine. Participants were regularly followed for the next two years to assess their response to treatment.

The study findings, published in the journal Nature Communications, show that 7 of the 10 patients showed improvement based on the American Spinal Injury Association’s Impairment Scale. Improvements included increased sensation when tested with a pinprick or light touch, increased muscle strength, and the recovery of voluntary bowel function. Three patients showed significant improvement, four had a moderate improvement, and three had no response.

This Mayo Clinic video shows how the process works:

Perhaps the most dramatic improvement was in Chris Barr, a California man who was paralyzed in 2017 while surfing near San Francisco. He broke his neck in eight places when his head hit the ocean floor.

Barr was the first person enrolled in the Mayo study. Eighteen months after the stem cell injection, Barr was able to walk again and continues to show improvement in his mobility and quality of life.

"I never dreamed I would have a recovery like this," Barr told ABC News. "I can feed myself. I can walk around. I can do day-to-day independent activities."  

No serious adverse events were reported from the stem cell treatment. The most common side effects were headaches and musculoskeletal pain that went away after over-the-counter medications were taken.

Since safety is the primary goal of a Phase 1 study, further research will be needed to assess the improvements in movement and sensation. The use of fat-derived stem cells for spinal cord injury is considered experimental by the Food and Drug Administration.

According to the National Spinal Cord Injury Statistical Center, nearly 300,000 Americans currently suffer from a spinal cord injury, costing the healthcare system over $40 billion annually.  The estimated lifetime cost for each patient can reach millions of dollars.

The spinal cord has limited ability to repair itself. Patients who suffer a significant injury typically experience most of their recovery in the first six to 12 months. Improvements generally stop 12 to 24 months after an injury. Only about 5% of people who are paralyzed can expect to regain any feeling or movement.

"For years, treatment of spinal cord injury has been limited to supportive care, more specifically stabilization surgery and physical therapy," Dr. Bydon says. "Many historical textbooks state that this condition does not improve. In recent years, we have seen findings from the medical and scientific community that challenge prior assumptions. This research is a step forward toward the ultimate goal of improving treatments for patients."

Mayo Clinic Research Shows Stem Cells May Treat Paralysis

By A. Rahman Ford, PNN Columnist

In a case report recently published in Mayo Clinic Proceedings, a 53-year-old California man paralyzed from the neck down in a surfing accident experienced dramatic improvement after an injection of his own stem cells.  

Chris Barr can walk again and has shown other improvements in his motor and sensory functions. His case is significant, because currently there is no FDA-approved therapy that can reverse the devastating life-changing effects of paralysis from spinal cord injuries.

Barr’s inspiring story can be seen in this video produced by the Mayo Clinic:

Barr was one of 10 paralyzed adults enrolled in a Phase I clinical trial that looked at the safety, side effects and ideal dose of stem cells. Early findings show that patient response varied. Mayo researchers call Barr a “superresponder” because his treatment was so successful.

"In this case report, the first patient was a superresponder, but there are other patients in the trial who are moderate responders and nonresponders," says first author Mohamad Bydon, MD, a Mayo Clinic neurologic surgeon. "One of our objectives in this study and future studies is to better delineate who will be a responder and why patients respond differently to stem cell injections.”

According to the National Spinal Cord Injury Statistical Center, about 288,000 Americans currently suffer from a spinal cord injury (SCI). Over 17,000 Americans suffer SCI’s each year, costing the health care system over $40 billion annually.  The estimated lifetime cost for each patient can range from the hundreds of thousands into the millions of dollars, and their life expectancy rates fall far below those without SCI.

Chronic pain is a serious problem that can result from SCI, affecting about two-thirds of patients, with one out of three reporting their pain as severe. With the inherent limitations of medical interventions such as surgery, medication and physical rehabilitation, new strategies are needed to improve functional outcomes and quality of life.

Although stem cells have  successfully been used to treat inflammatory conditions that affect the spinal cord, such as arachnoiditis, published reports on their safety and effectiveness in treating SCI‘s are scant.

Animal studies have demonstrated effectiveness in treating SCI with embryonic stem cells and human neural stem cells. Mesenchymal stem cells (MSC’s) derived from bone marrow have also been successfully used to treat SCI in rats, as have human umbilical cord-derived stem cells. And adipose stem cells derived from fat have been used to improve functional recovery in dogs with SCI.

Barr’s Impressive Results

After being paralyzed in the surfing accident, Chris Barr’s condition initially improved after a posterior cervical decompression and fusion. However, that improvement plateaued after six months. Barr had complete loss of motor function below the site of his injury, including bowel and bladder sensation.

Barr enrolled in the Mayo study nine months after his injury. His stem cells were collected by taking a small amount of fat from his abdomen. Over eight weeks, the cells were grown in the laboratory to 100 million cells. Those MSC cells were then injected into Barr’s lower back, 11 months after his injury.

The results from the therapy were impressive and long lasting. Eighteen months after stem cell injection, Barr’s total upper extremity motor score increased from 35 to 44. There was also considerable improvement in his total lower extremity motor scores, from 36 to 49. Improvement in sensory scores was likewise remarkable.

Barr reported significant improvement in his quality of life, as well as mental and physical health. He was able to walk further, faster and for a longer period of time. His range of motion for shoulder flexion and shoulder abduction also improved.

“Given the multidimensional complexity of SCI, cell-based therapies have offered substantial promise as a therapeutic strategy because of the multifactorial roles that stem cells can potentially provide,” Bydon wrote.

Bydon and his colleagues caution in generalizing from Barr’s remarkable results, although there is cause for optimism. The Mayo team plans to continue analyzing patient responses, and further results will be published on the other nine trial participants.

A. Rahman Ford, PhD, is a lawyer and research professional. He is a graduate of Rutgers University and the Howard University School of Law, where he served as Editor-in-Chief of the Howard Law Journal.

Rahman lives with chronic inflammation in his digestive tract and is unable to eat solid food. He has received stem cell treatment in China. 

This column is not intended as medical advice and represent the author’s opinions alone. It does not inherently express or reflect the views, opinions and/or positions of Pain News Network.